Cefaly Device for Migraine Relief and Prevention

The Cefaly device is a small, wearable neurostimulator that sits on the forehead and sends mild electrical pulses through the skin to the supraorbital branch of the trigeminal nerve, one of the main nerves involved in migraine. It was the first transcutaneous nerve stimulation device cleared by the FDA specifically for migraine, and it now has clearance for both preventing attacks and treating them once they start. The clinical evidence behind it is moderate rather than overwhelming, but it consistently shows real benefits over sham stimulation, with a safety profile that makes most prescription migraine drugs look rough by comparison.

What the Device Actually Does to Your Nerves

The Cefaly sticks to the center of your forehead with a small adhesive electrode and delivers biphasic electrical impulses at 60 Hz. During a preventive session, the intensity gradually ramps from 1 to 16 milliamps over about 14 minutes, and the full session lasts 20 minutes. You feel a tingling or buzzing sensation across your forehead that most people describe as odd but tolerable. A separate acute-treatment setting uses a higher intensity and is meant to be turned on when a migraine attack is already underway.

The electrical current targets the supraorbital nerve, which is a branch of the trigeminal nerve, the large cranial nerve that carries sensation from your face and plays a central role in migraine pathology. Early thinking assumed that stimulating this nerve directly blocked pain signals traveling up to the brain. That hypothesis did not hold up well in follow-up research. Instead, the device appears to work through slower, indirect neuromodulatory pathways involving areas of the brain that regulate pain processing and emotional responses to pain, particularly a region called the perigenual anterior cingulate cortex.¹ This is worth knowing because it helps explain why the device works better as a daily preventive habit than as a one-time intervention, and why it sometimes takes weeks of consistent use to see meaningful improvement.

How Well It Prevents Migraines

The strongest evidence for Cefaly is in migraine prevention, meaning daily use to reduce how often attacks happen. In the pivotal randomized, sham-controlled trial that led to FDA clearance, people who used the real device daily for three months saw their average migraine days drop from about 7 per month to under 5. The sham group barely budged. Roughly 38% of real-device users hit the standard clinical benchmark of at least a 50% reduction in monthly migraines, compared to about 12% in the sham group.² Monthly use of acute migraine medications also dropped significantly in the treatment group but not in the sham group.

Those numbers are modest compared to some of the newer anti-CGRP monoclonal antibodies, which tend to produce 50% responder rates in the range of 40–60% depending on the population. But they are meaningful, particularly for a treatment with almost no systemic side effects. For chronic migraine specifically, which involves 15 or more headache days per month, an open-label trial found that headache days dropped by about three days per month and acute medication intake fell by roughly 31% after three months of daily use.³ A separate open-label study in chronic migraine patients reported that about 35% of enrolled patients met their study endpoints, and over half significantly cut their use of acute medication.⁴

The pattern across trials is consistent: the device reliably reduces migraine frequency and medication use, but it does not eliminate migraines for most people. If you go in expecting a cure, you will be disappointed. If you go in hoping to have fewer bad days per month and to take fewer triptans or NSAIDs, the odds are reasonable.

Using It During an Attack

The acute-treatment mode is a newer addition. The idea is that you put the device on at the onset of a migraine and run a one-hour session at higher intensity. In the largest sham-controlled trial of this use, about a quarter of people using the real device were pain-free at two hours, versus about 18% in the sham group, a therapeutic gain of roughly 7 percentage points.⁵ Where the device showed stronger separation from sham was in pain relief (not complete freedom, but a meaningful drop in severity), which was about 70% in the real group versus 55% in the sham group. Resolution of the most bothersome associated symptom, such as nausea, light sensitivity, or sound sensitivity, also favored the real device, with roughly 56% versus 42% achieving relief.

An earlier pilot study produced more impressive numbers, with about 35% of subjects achieving pain freedom at two hours and over 70% reporting pain relief.⁶ Pilot studies tend to run hotter than large confirmatory trials, so the more conservative numbers from the larger trial are probably closer to what a typical user should expect.

To put the acute numbers in context, triptans, the most widely used class of prescription acute migraine drugs, typically produce pain freedom at two hours in about 25–35% of patients in controlled trials. So Cefaly’s acute performance lands in a similar ballpark for pain freedom, though the comparison is not perfect because the trial populations and sham controls differ. The real advantage of the device for acute use is not that it outperforms triptans but that it has almost no side effects, does not cause medication-overuse headache from frequent use, and can be combined with medications when needed.

Safety and Side Effects

The safety profile of the Cefaly device is genuinely one of its strongest selling points, and the data here is unusually robust. A large survey of over 2,300 users in the general population found that about 4.3% reported any side effect at all, and none of those side effects were serious.⁷ The most common complaint was local discomfort or intolerance to the tingling sensation, reported by about 2% of users. Less than 1% experienced sleepiness or fatigue, and about half a percent got a headache after the session. Skin allergy to the electrode gel was extremely rare, occurring in under 0.1%.

A study of the device in Japanese migraine patients confirmed the same pattern: a small number of participants reported tingling at the site, sleepiness, or a feeling that the stimulus was too strong, and no severe adverse events were observed.⁸ Three people in that study dropped out due to side effects, but those effects resolved when they stopped using the device.

Compare that to common preventive migraine medications: topiramate can cause cognitive fog, weight loss, tingling in the extremities, and kidney stones; beta-blockers cause fatigue and exercise intolerance; amitriptyline causes dry mouth, weight gain, and drowsiness. Even the newer CGRP-targeting drugs, which have favorable side-effect profiles by pharmaceutical standards, still carry risks of constipation and injection-site reactions. The Cefaly’s worst common side effect is that the forehead tingling feels annoying.

Where It Fits in Migraine Treatment Guidelines

The International Headache Society released evidence-based guidelines on non-invasive neuromodulation devices for migraine, and Cefaly received a “weak recommendation” for both acute and preventive treatment.⁹ That phrasing might sound discouraging, but it reflects the overall evidence quality for the entire category of neuromodulation devices, not a particular concern about Cefaly’s safety or efficacy. A “weak recommendation” in guideline language means the evidence shows benefit but is not yet robust enough for a strong universal recommendation. Every other device in this class received the same rating or lower.

In practice, most headache specialists position Cefaly as a reasonable option in several scenarios: for people who want to avoid daily medication altogether, for those who have not tolerated multiple preventive drugs, for people who are already on medication and want to add a non-drug layer, or for anyone who has medical reasons to minimize pharmaceuticals. Its favorable safety profile makes it particularly appealing for patients with other health conditions or those already taking multiple medications.¹⁰

The Placebo Question

Any device that delivers a physical sensation on the body raises an obvious question: how much of the benefit is placebo? This is harder to control for than with a pill, because people can feel whether the device is doing something. The sham conditions used in Cefaly trials deliver stimulation at a very low intensity, too low to produce therapeutic nerve modulation but enough to create a mild sensation so that participants cannot easily tell if they have the real device or the fake one. Still, the blinding is imperfect, and some researchers argue that any tingling device will have an amplified placebo response compared to a sugar pill.

The acute trial data illustrates this tension clearly. The sham group’s 18% pain-freedom rate at two hours is higher than you would typically expect from a pure placebo in migraine trials, where inert pill placebos tend to produce pain freedom in about 10–15% of subjects. That elevated sham response narrows the gap between real and fake, making the real device’s roughly 26% rate look less impressive than it might otherwise be. But the statistical separation was still significant, and the secondary endpoints showed larger differences favoring the real device.¹¹ For prevention, the sham-controlled trial showed the same pattern: real beats sham, but sham is not zero.

The honest answer is that some of the benefit any given person experiences from Cefaly is probably placebo-related, as is true of essentially every migraine treatment including drugs. What matters clinically is whether the total benefit, pharmacological or not, exceeds the risks and costs. Given that the risks are close to zero, even a modest pharmacological effect stacked on top of a robust placebo effect is arguably a good deal.

Pregnancy and Pediatric Use

Two populations stand out as especially interesting candidates for Cefaly: pregnant people and children. In both groups, the usual toolbox of preventive migraine drugs is sharply limited. Topiramate is associated with birth defects. Most first-line preventives are either contraindicated or carry warnings during pregnancy. The newer CGRP drugs have not been adequately studied in pregnancy. This leaves pregnant migraine sufferers in a difficult spot, often limited to acetaminophen, which is a weak migraine treatment at best.

A review of neuromodulation for headache management in pregnancy concluded that while direct evidence from pregnant populations is limited, neuromodulatory devices are considered safe and well-tolerated non-pharmacological options that may serve as a therapeutic alternative or supplement for pregnant patients.¹² Since the device works by sending mild electrical impulses through the skin of the forehead without any systemic drug exposure, the theoretical risk to the fetus is negligible. That said, no large randomized trial has been conducted specifically in pregnant women, so the recommendation rests on extrapolation from the general safety data rather than direct evidence.

For children, a retrospective review from a pediatric headache treatment center found that the Cefaly device produced a large effect size for reducing headache intensity, comparable to acupuncture and intravenous migraine cocktails in that same clinic setting.¹³ This is preliminary evidence from a single center’s experience, not a randomized controlled trial, but it is encouraging enough that pediatric headache specialists increasingly consider the device as an option, particularly for families who prefer a drug-free approach.

What Daily Use Actually Looks Like

The practical experience of using Cefaly is worth discussing because it affects adherence, and adherence is the main determinant of whether the device works for prevention. You are committing to sitting with a small device stuck to your forehead for 20 minutes every day, ideally at a consistent time. Many users do their session before bed, since the gentle stimulation can cause drowsiness. The electrode pads are disposable and need to be replaced regularly, which adds an ongoing cost on top of the device itself. A single Cefaly Dual unit currently retails for several hundred dollars, and the electrode pads cost extra.

The tingling sensation takes some getting used to. Most people acclimate within the first few sessions, but a small fraction find it genuinely unpleasant. In the large safety survey, about 2% stopped using the device specifically because of this discomfort.¹⁴ If you’re someone with scalp allodynia, where even light touch on the head causes pain during a migraine, you may find the sensation harder to tolerate during an attack.

The device does not require a prescription in the United States, though many insurance plans will not cover it. Some headache specialists will write a letter of medical necessity to help with reimbursement, and HSA or FSA funds can typically be used for the purchase. The cost is competitive with a few months of brand-name preventive migraine medication, but unlike a prescription, the upfront outlay is concentrated into one purchase rather than spread over copays.

Who Does Not Respond

The clinical trials make it clear that Cefaly does not work for everyone. In the prevention trial, roughly 62% of people using the real device did not hit the 50% reduction benchmark. In the acute trial, about three-quarters of real-device users were not pain-free at two hours. These non-response rates are not unusual for migraine treatments; the same is true of triptans, beta-blockers, and even CGRP drugs. Migraine is a heterogeneous condition, and no single treatment works across the board.

There are currently no reliable predictors of who will respond to Cefaly and who won’t. Some clinicians report anecdotally that patients with prominent forehead and periorbital pain during attacks seem to do better, which would make anatomical sense given the nerve being stimulated, but this has not been validated in a study. The general guidance from headache experts is to commit to at least two to three months of daily preventive use before judging whether it is helping, because the neuromodulatory effects build gradually.

Beyond Migraine

Because the Cefaly device modulates trigeminal nerve activity, researchers have explored whether it might help with other headache types. A review of transcutaneous pericranial stimulation techniques noted that the results are encouraging for different kinds of headache and that neuromodulatory approaches are expanding possibilities for patients who have not responded to traditional drug therapy.¹⁵ Tension-type headache is the most obvious adjacent candidate, since it often involves referred pain from the same trigeminal territory, though formal trial data for that indication is thin.

There is also speculative interest in the device’s potential for conditions beyond headache entirely. The observation that Cefaly appears to modulate the perigenual anterior cingulate cortex, a brain region involved in both pain perception and emotional regulation, has led some researchers to suggest it could theoretically be useful in conditions like fibromyalgia or depression. These are entirely hypothetical applications at this point and should not be mistaken for clinical evidence, but they illustrate how the mechanism of action might have broader reach than the current FDA clearance implies. For now, the device is approved for migraine and that is where the evidence lives.